Polaryx Therapeutics (NASDAQ:PLYX) Releases Quarterly Earnings Results

Polaryx Therapeutics (NASDAQ:PLYX) issued its quarterly earnings results on Friday. The company reported ($0.05) earnings per share for the quarter, FiscalAI reports.

Polaryx Therapeutics Stock Performance

Shares of PLYX stock opened at $2.67 on Friday. Polaryx Therapeutics has a one year low of $2.20 and a one year high of $48.91. The company’s fifty day moving average price is $5.35.

Analyst Ratings Changes

Several research analysts have recently weighed in on PLYX shares. Maxim Group started coverage on shares of Polaryx Therapeutics in a research note on Friday, February 27th. They set a “buy” rating and a $10.00 price target on the stock. Weiss Ratings initiated coverage on shares of Polaryx Therapeutics in a research note on Friday, April 24th. They set a “sell (e-)” rating on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Polaryx Therapeutics presently has a consensus rating of “Hold” and an average target price of $10.00.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.